Rhythm announced that Lex Van der Ploeg, PhD, has joined the company as chief scientific officer.
Van der Ploeg brings more than 25 years of drug development expertise in obesity, metabolic diseases, and other therapeutic areas.
“Lex has considerable experience with the biology and genetics of the metabolic pathways we are targeting with our ghrelin and melanocortin 4 receptor clinical programs,” says Keith Gottesdiener, MD, chief executive officer of Rhythm.
Van der Ploeg’s experience includes 17 years at Merck Research Laboratories, where he directed drug development programs in metabolism, oncology, and neurodegenerative diseases. “I am very pleased to join this team to help develop this portfolio of drug candidates for obesity, diabetes, and GI metabolic disorders,” says Van der Ploeg.
Release Date: Nov. 30, 2011